IL2 and cancer: PD-1/PD-L1 binding has been demonstrated to block the effector function and motility of most lymphocytes, thereby decreasing the production of IL-2 (interleukin-2) by helper T-cells and diminishing the clonal proliferation of cytotoxic T-cells in response to cancer cells44.